ArticleFrontiers in pharmacology2025

Beyond efficacy parity: a novel cost-equilibrium framework for value assessment of competing third-line therapies in metastatic colorectal cancer.

Shunlong Ou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.